Elanco Animal Health (NYSE:ELAN) Updates Q1 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its first quarter earnings guidance on Tuesday. The company provided EPS guidance of $0.29-$0.34 for the period, compared to the consensus EPS estimate of $0.30. The company issued revenue guidance of $1.155-$1.180 billion, compared to the consensus revenue estimate of $1.21 billion. Elanco Animal Health also updated its FY25 guidance to $0.80-$0.86 EPS.

Analyst Ratings Changes

ELAN has been the topic of several research reports. Leerink Partners assumed coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Barclays increased their price target on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. UBS Group began coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective on the stock. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus reduced their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $16.00.

Elanco Animal Health Stock Up 1.0 %

Shares of NYSE:ELAN opened at $11.14 on Tuesday. The company has a market cap of $5.50 billion, a price-to-earnings ratio of 27.84, a PEG ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 12 month low of $10.77 and a 12 month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $11.78 and a 200 day moving average price of $13.09.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.08 earnings per share. As a group, equities research analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.